2017

150.00 rub.
Buy article
2017/№3

Role of heart rate in mechanisms of compensation and decompensation in patients with CHF and sinus rhythm or atrial fibrillation and methods for safe and effective control of the heart rhythm. Part 1. Sinus rhythm

Mareev V. Yu.1, Mareev Yu. V.2
1 – Federal State Budgetary Educational Institution of Higher Education "M. V. Lomonosov Moscow State University", Leninskie Gory 1, GSP-1, Moscow 119991 2 – Robertson Centre for Biostatistics - University of Glasgow Boyd Orr Building University Avenue, Glasgow, Great Britain. G12 8QQ

Keywords: chronic heart failure, heart rate, sinus rhythm, atrial fibrillation, control of heart rhythm

DOI: 10.18087/rhfj.2017.3.2352

This review focuses on the role of heart rate in patients with CHF and reduced LV EF with sinus rhythm or atrial fibrillation. Methods of heart rate control for improving the course of disease and prognosis for patients with CHF are also discussed.
  1. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13(5):255–66 [Mareev Yu. V., Gerasimova V. V., Goryunova T. V., Petruxina A. A., Danielyan M. O., Kapanadze L. G. i dr. Faktory`, opredelyayushhie prognoz pri xronicheskoj serdechnoj nedostatochnosti: rol` shiriny` i morfologii kompleksa QRS. Zhurnal Serdechnaya Nedostatochnost`. 2012;13(5):255–66].
  2. McMurray JJV. It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? Eur Heart J. 2015;36(31):2047–9. DOI:10.1093/eurheartj/ehv190.
  3. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56(5):392–406. DOI:10.1016/j.jacc.2010.05.011.
  4. Петрухина А. А., Мареев В. Ю., Скворцов А. А., Белявский Е. А., Хеймец Г. И., Беленков Ю. Н. Влияние спиронолактона и дигоксина на прогноз больных ХСН. Результаты 30-летнего наблюдения. Журнал Сердечная Недостаточность. 2008;9(3):123–7. DOI:10.18087/rhfj.2008.3.1086 [Petruxina A. A., Mareev V. Yu., Skvorczov A. A., Belyavskij E. A., Xejmecz G. I., Belenkov Yu. N. Vliyanie spironolaktona i digoksina na prognoz bol`ny`x XSN. Rezul`taty` 30-letnego nablyudeniya. Zhurnal Serdechnaya Nedostatochnost`. 2008;9(3):123–7. DOI:10.18087/rhfj.2008.3.1086].
  5. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения хронической сердечной недостаточности. –М.: Медиа Медика; 2000. 266 с [Belenkov Yu. N., Mareev V. Yu. Princzipy` raczional`nogo lecheniya xronicheskoj serdechnoj nedostatochnosti. –M.: Media Medika; 2000. 266 s].
  6. Bowditch HP Uber die Eigenthfimlichkeiten der eizbarkeit, welche die Muskelfasern des Herzens zeigen. Bet S/ichs Ges (Akad) Wiss (1871) pp 652–689.
  7. Alpert NR, Mulieri LA, Warshaw D. The failing human heart. Cardiovasc Res. 2002;54(1):1–10.
  8. Böhm M, La Rosée K, Schmidt U, Schulz C, Schwinger RH, Erdmann E. Force-frequency relationship and inotropic stimulation in the nonfailing and failing human myocardium: implications for the medical treatment of heart failure. Clin Investig. 1992;70(5):421–5.
  9. Heusch G. Heart rate and heart failure. Not a simple relationship. Circ J. 2011;75(2):229–36.
  10. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 1994;15(2):164–70.
  11. Киселева З. М., Орлова А. И. Исследование катехоламинов и ДОФА при лечении обзиданом больных с недостаточностью кровоснабжения. Терапевтический архив. 1979;51(1):49–53 [Kiseleva Z. M., Orlova A. I. Issledovanie katexolaminov i DOFA pri lechenii obzidanom bol`ny`x s nedostatochnost`yu krovosnabzheniya. Terapevticheskij arxiv. 1979;51(1):49–53].
  12. Киселева З. М., Орлова А. И. Функциональное состояние симпато-адреналовой системы у больных инфекционно-аллергическим миокардитом и идиопатическим поражением миокарда под влиянием лечения сердечными гликозидами и бета-блокаторами. Терапевтический архив. 1978;50(8):38–43 [Kiseleva Z. M., Orlova A. I. Funkczional`noe sostoyanie simpato-adrenalovoj sistemy` u bol`ny`x infekczionno-allergicheskim miokarditom i idiopaticheskim porazheniem miokarda pod vliyaniem lecheniya serdechny`mi glikozidami i beta-blokatorami. Terapevticheskij arxiv. 1978;50(8):38–43].
  13. Cohn JN. Plasma norepinephrine and mortality. Clin Cardiol. 1995;18(3 Suppl I):I9-12.
  14. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts. New England Journal of Medicine. 1982;307(4):205–11. DOI:10.1056/NEJM198207223070401.
  15. Böhm M, La Rosée K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25(1):146–53.
  16. Goldspink DF, Burniston JG, Ellison GM, Clark WA, Tan L-B. Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol. 2004;89(4):407–16. DOI:10.1113/expphysiol.2004.027482.
  17. van Veldhuisen DJ, Brodde OE, van Gilst WH, Schulze C, Hegeman H, Anthonio RL et al. Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. Cardiovasc Res. 1995;30(3):386–93.
  18. Скворцов А. А., Челмакина С. М., Пожарская Н. И., Мареев В. Ю. Модулирование активности системы нейрогуморальной регуляции при хронической сердечной недостаточности Блокада ренин-ангиотензин-альдостероновой системы. Российский медицинский журнал. 2000;(2):87 [Skvorczov A. A., Chelmakina S. M., Pozharskaya N. I., Mareev V. Yu. Modulirovanie aktivnosti sistemy` nejrogumoral`noj regulyaczii pri xronicheskoj serdechnoj nedostatochnosti Blokada renin-angiotenzin-al`dosteronovoj sistemy`. Rossijskij mediczinskij zhurnal. 2000;(2):87].
  19. Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Нейрогормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? Журнал Сердечная Недостаточность. 2000;1(4):135–8 [Belenkov Yu. N., Ageev F. T., Mareev V. Yu. Nejrogormony` i czitokiny` pri serdechnoj nedostatochnosti: novaya teoriya starogo zabolevaniya? Zhurnal Serdechnaya Nedostatochnost`. 2000;1(4):135–8].
  20. Сычев А. В., Мареев В. Ю. Антицитокиновая терапия в лечении больных с хронической сердечной недостаточностью. Кардиология. 2010;50(5):77–83 [Sy`chev A. V., Mareev V. Yu. Anticzitokinovaya terapiya v lechenii bol`ny`x s xronicheskoj serdechnoj nedostatochnost`yu. Kardiologiya. 2010;50(5):77–83].
  21. Меерсон Ф. З. Адаптация сердца к большой нагрузке и сердечная недостаточность. –М.: Наука; 1975. 263 с [Meerson F. Z. Adaptacziya serdcza k bol`shoj nagruzke i serdechnaya nedostatochnost`. –M.: Nauka; 1975. 263 s].
  22. Nagueh SF, Mikati I, Kopelen HA, Middleton KJ, Quiñones MA, Zoghbi WA. Doppler estimation of left ventricular filling pressure in sinus tachycardia. A new application of tissue doppler imaging. Circulation. 1998;98(16):1644–50.
  23. Muntinga HJ, Gosselink AT, Blanksma PK, De Kam PJ, Van Der Wall EE, Crijns HJ. Left ventricular beat to beat performance in atrial fibrillation: dependence on contractility, preload, and afterload. Heart. 1999;82(5):575–80.
  24. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. British Journal of Pharmacology. 2008;153(8):1589–601. DOI:10.1038/sj.bjp.0707673.
  25. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальныйэтап). Журнал Сердечная Недостаточность. 2011;12(2):63–8. DOI:10.18087/ rhfj.2011.2.1510 [Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Fomin I. V., Badin Yu. V., Polyakov D. S. i dr. Istinnaya rasprostranennost` XSN v Evropejskoj chasti Rossijskoj Federaczii (issledovanie E`POXA, gospital`ny`j e`tap). Zhurnal Serdechnaya Nedostatochnost`. 2011;12(2):63–8. DOI:10.18087/rhfj.2011.2.1510].
  26. Lechat P. Beta-blocker treatment in heart failure. Role of heart rate reduction. Basic Res Cardiol. 1998;93 Suppl 1:148–55.
  27. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В., и др. Эпидемиологическая программа ЭПОХА–ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д–ХСН). Журнал Сердечная Недостаточность. 2016;17(6):299–305. DOI:10.18087/rhfj.2016.5.2239 [Polyakov D. S., Fomin I. V., Valikulova F. Yu., Vajsberg A. R., Kraiem N., Badin Yu. V., i dr. E`pidemiologicheskaya programma E`POXA–XSN: dekompensacziya xronicheskoj serdechnoj nedostatochnosti v real`noj klinicheskoj praktike (E`POXA–D–XSN). Zhurnal Serdechnaya Nedostatochnost`. 2016;17(6):299–305. DOI:10.18087/ rhfj.2016.5.2239].
  28. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004;26(7–8):637–44.
  29. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66(2):133–44.
  30. Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis.CMAJ. 2016;188(3):E53-63. DOI:10.1503/cmaj.150535.
  31. Zhang D, Wang W, Li F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta-analysis. Canadian Medical Association Journal. 2016;188(15):E384–92. DOI:10.1503/cmaj.160050.
  32. Jouven X, Zureik M, Desnos M, Guérot C, Ducimetière P. Resting heart rate as a predictive risk factor for sudden death in middleaged men. Cardiovasc Res. 2001;50(2):373–8.
  33. Diaz A. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal. 2005;26(10):967–74. DOI:10.1093/eurheartj/ehi190.
  34. Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004;27(2):80–6.
  35. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. DOI:10.1093/eurheartj/eht296.
  36. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal. 2009;30(19):2337–45. DOI:10.1093/eurheartj/ehp358.
  37. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. The Lancet. 2010;376(9744):886–94. DOI:10.1016/S0140-6736(10)61259-7.
  38. Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. New England Journal of Medicine. 2014;371(12):1091–9. DOI:10.1056/NEJMoa1406430.
  39. Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker–Induced Heart Rate Lowering and Cardioprotection in Hypertension. Journal of the American College of Cardiology. 2008;52(18):1482–9. DOI:10.1016/j.jacc.2008.06.048.
  40. Cockcroft JR. Atenolol Is Dead: Long Live Beta-Blockade. Journal of the American College of Cardiology. 2009;53(22):2102. DOI:10.1016/j.jacc.2008.12.076.
  41. Salles GF, Cardoso CRL, Fonseca LL, Fiszman R, Muxfeldt ES. Prognostic Significance of Baseline Heart Rate and Its Interaction With Beta-Blocker Use in Resistant Hypertension: A Cohort Study. American Journal of Hypertension. 2013;26(2):218–26. DOI:10.1093/ajh/hps004.
  42. Palatini P, Reboldi G, Beilin LJ, Eguchi K, Imai Y, Kario K et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. International Journal of Cardiology. 2013;168(2):1490–5. DOI:10.1016/j.ijcard.2012.12.103.
  43. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT et al. Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension. The American Journal of Cardiology. 2012;109(5):685–92. DOI:10.1016/j.amjcard.2011.10.025.
  44. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J. 2005;26(10):943–5. DOI:10.1093/eurheartj/ehi235.
  45. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327–34. DOI:10.1093/eurheartj/ehn123.
  46. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823–30. DOI:10.1016/j.jacc.2007.04.079.
  47. Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation? JACC: Heart Failure. 2014;2(3):213–20. DOI:10.1016/j.jchf.2014.01.005.
  48. Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection FractionCLINICAL PERSPECTIVE: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8(5):871–9. DOI:10.1161/CIRCHEARTFAILURE.115.002285.
  49. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376(9744):875–85. DOI:10.1016/S0140-6736(10)61198-1.
  50. Narahara KA, Blettel ML. Effect of rate on left ventricular volumes and ejection fraction during chronic ventricular pacing. Circulation. 1983;67(2):323–9.
  51. Rozkovec A, Papouchado M, James MA, Kendrick AH, Clarke LM, Rees JR. The relationship of symptoms to performance in paced patients with breathlessness. European Heart Journal. 1989;10(1):63–9.
  52. Rao K, Fisher ML, Robinson S, Shorofsky S, Gottlieb SS. Effect of chronic changes in heart rate on congestive heart failure. J Card Fail. 2007;13(4):269–74. DOI:10.1016/j.cardfail.2006.12.001.
  53. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115–23.
  54. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II – DAVIT II). Am J Cardiol. 1990;66(10):779–85.
  55. The Multicenter Diltiazem Postinfarction Trial Research Group. The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction. New England Journal of Medicine. 1988;319(7):385–92. DOI:10.1056/NEJM198808183190701.
  56. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52–60.
  57. Claro JC, Candia R, Rada G, Baraona F, Larrondo F, Letelier LM. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. В: The Cochrane Collaboration, редактор. Cochrane Database of Systematic Reviews [Интернет]. -Chichester, UK: John Wiley & Sons, Ltd; 2015 [Claro JC, Candia R, Rada G, Baraona F, Larrondo F, Letelier LM. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. V: The Cochrane Collaboration, redaktor. Cochrane Database of Systematic Reviews [Internet]. -Chichester, UK: John Wiley & Sons, Ltd; 2015].
  58. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. DOI:10.1056/NEJMoa043399.
  59. Cohn JN. The sympathetic nervous system in heart failure. J Cardiovasc Pharmacol. 1989;14 Suppl 5:S57-61.
  60. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984;101(3):370–7.
  61. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
  62. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.
  63. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al. Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 2009;53(23):2150–8. DOI:10.1016/j.jacc.2009.02.046.
  64. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55. DOI:10.1056/NEJM199605233342101.
  65. Belenkov IN, Skvortsov AA, Mareev VI, Nasonova SN, Sychev AV, Narusov OI et al. [Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]. Kardiologiia. 2003;43(10):10–21.
  66. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–94.
  67. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2013;1(1):21–8. DOI:10.1016/j.jchf.2012.09.002.
  68. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet. 2014;384(9961):2235–43. DOI:10.1016/S0140-6736(14)61373-8.
  69. Thackray SDR, Ghosh JM, Wright GA, Witte KKA, Nikitin NP, Kaye GC et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers. American Heart Journal. 2006;152(4):713.e9-713.e13. DOI:10.1016/j.ahj.2006.07.007.
  70. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L et al. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose? Journal of the American College of Cardiology. 2012;59(22):1938–45. DOI:10.1016/j.jacc.2012.01.020.
  71. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102(1):11–22. DOI:10.1007/s00392-012-0467-8.
  72. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8.
  73. Tardif J-C, O’Meara E, Komajda M, Böhm M, Borer JS, Ford I et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal. 2011;32(20):2507–15. DOI:10.1093/eurheartj/ehr311.
  74. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure. 2013;15(5):551–9. DOI:10.1093/eurjhf/hft010.
  75. Alicandri C, Fariello R, Boni E, Zaninelli A, Castellano M, Beschi M et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol. 1987;9 Suppl 2:S61-67.
  76. Нарусов О. В., Мареев В. Ю., Скворцов А. А. Клинические, гемодинамические и нейрогуморальные эффекты дигоксина у больных с ХСН. Журнал Сердечная Недостаточность. 2000;1(1):26–30 [Narusov O. V., Mareev V. Yu., Skvorczov A. A. Klinicheskie, gemodinamicheskie i nejrogumoral`ny`e e`ffekty` digoksina u bol`ny`x s XSN. Zhurnal Serdechnaya Nedostatochnost`. 2000;1(1):26–30].
  77. van Veldhuisen DJ, Man in ’t Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;22(6):1564–73.
  78. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;h4451. DOI:10.1136/bmj.h4451.
  79. Jorge E, Baptista R, Martins H, Saraiva F, Costa S, Vieira H et al. Digoxin in advanced heart failure patients: A question of rhythm. Revista Portuguesa de Cardiologia. 2013;32(4):303–10. DOI:10.1016/j.repc.2012.11.007.
  80. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. International Journal of Cardiology. 2008;123(2):138–46. DOI:10.1016/j.ijcard.2006.12.001.
  81. Runge TM. Clinical implications of differences in pharmacodynamic action of polar and nonpolar cardiac glycosides. Am Heart J. 1977;93(2):248–55.
  82. Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol. 1985;5(5 Suppl A):35A–42A.
  83. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989;80(1):65–77.
  84. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989;13(1):134–42.
  85. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329(1):1–7. DOI:10.1056/NEJM199307013290101.
  86. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22(4):955–62.
  87. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33. DOI:10.1056/NEJM199702203360801.
  88. Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal. 2012;33(9):1137–41. DOI:10.1093/eurheartj/ehs004.
  89. Vangeli RS, Naumov VG, Blank ML, Sergakova LM, Grigoriants RA. [Anti-arrhythmia and arrhythmogenic actions of digoxin in ventricular rhythm disorders in patients with circulatory insufficiency]. Ter Arkh. 1987;59(9):81–6.
  90. Channer KS, James MA, MacConnell T, Rees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol. 1994;37(1):53–7.
  91. Channer KS, Papouchado M, James MA, Pitcher DW, Rees JR. Towards improved control of atrial fibrillation. European Heart Journal. 1987;8(2):141–7.
  92. Ledwitch KV, Barnes RW, Roberts AG. Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein. Bioscience Reports. 2016;36(2):e00309–e00309. DOI:10.1042/BSR20150317.
  93. Мухарлямов Н. М., Мареев В. Ю. Лечение хронический сердечной недостаточности. -М.: Медицина; 1985. 208 с [Muxarlyamov N. M., Mareev V. Yu. Lechenie xronicheskij serdechnoj nedostatochnosti. –M.: Mediczina; 1985. 208 s].
  94. Rich MW, McSherry F, Williford WO, Yusuf S, Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38(3):806–13.
  95. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–11. DOI:10.1056/NEJMoa021266.
  96. Moulias S, Tigoulet F, Meaume S. Digoxin for the treatment of heart failure. N Engl J Med. 2003;348(7):661-663; author reply 661-663. DOI:10.1056/NEJM200302133480718.
  97. Testani JM, Brisco MA, Tang WHW, Kimmel SE, Tiku-Owens A, Forfia PR et al. Potential Effects of Digoxin on Long-Term Renal and Clinical Outcomes in Chronic Heart Failure. Journal of Cardiac Failure. 2013;19(5):295–302. DOI:10.1016/j.cardfail.2013.03.002.
  98. Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF et al. Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association. 2015;4(4):e001626–e001626. DOI:10.1161/JAHA.114.001626.
Mareev V. Yu., Mareev Yu. V. Role of heart rate in mechanisms of compensation and decompensation in patients with CHF and sinus rhythm or atrial fibrillation and methods for safe and effective control of the heart rhythm. Part 1. Sinus rhythm. Russian Heart Failure Journal. 2017;18(3):213–224

To access this material please log in or register

Register Authorize
Ru En